Results 11 to 20 of about 145,320 (184)

Containing anti-PLA2R IgG antibody induces podocyte injury in idiopathic membranous nephropathy

Renal Failure, 2023
Background: Idiopathic membranous nephropathy is widely recognized as an autoimmune kidney disease that is accompanied by the discovery of several autoantibodies, and the antibody subclass in the circulation of patients with iMN is mainly IgG. However, the direct pathogenic effect of the containing anti-PLA2R IgG antibody on podocytes is not clear ...
Baobao Wang, Xueqing Tang, Zunsong Wang   +2 more
exaly   +5 more sources

Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy.

PLoS ONE, 2016
The phospholipase A2 receptor (PLA2R) is the major target antigen (Ag) in idiopathic membranous nephropathy (IMN). Recently, several types of immunoassay systems for anti-PLA2R antibody (Ab) have been developed.
Kei Hihara, Masayuki Iyoda, Shohei Tachibana, Ken Iseri, Tomohiro Saito, Yasutaka Yamamoto, Taihei Suzuki, Yukihiro Wada, Kei Matsumoto, Takanori Shibata   +9 more
doaj   +3 more sources

The significance of anti-PLA2R antibody in the diagnosis and treatment of primary membranous nephropathy

Linchuang shenzangbing zazhi, 2019
Primary membranous nephropathy(PMN) is a glomerulus-specific autoimmune disorder mainly caused by challenge of autoantibodies against the recently discovered antigens located on podocytes, such as the M-type phospholipase A2 receptor(PLA2R), the ...
XU Dong-mei, LIU Yi-peng
doaj   +2 more sources

Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy [PDF]

American Journal of Nephrology, 2015
<b><i>Background:</i></b> The natural course of idiopathic membranous nephropathy (MN) varies, as it is known through favorable outcomes in most patients. However, one third of patients with idiopathic MN will slowly progress to end-stage renal disease (ESRD). To prevent disease progression, patients at high risk to develop ESRD
Timmermans, Sjoerd A. M. E. G., Hamid, Myrurgia A. Abdul, Tervaert, Jan Willem Cohen, Damoiseaux, Jan G. M. C., van Paassen, Pieter   +4 more
openaire   +4 more sources

Analysis of glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy in the background of different serum anti-PLA2R levels

Renal Failure, 2022
Objective To verify glomerular PLA2R antigen and serum PLA2R antibody expression in membranous nephropathy as well as to explore glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy (IMN) in the background of ...
Yuemeng Sun, Ping Lan, Jie Feng, Zhigang Wang, Chao Liu, Liyi Xie, Xiaoyang Yu   +6 more
doaj   +3 more sources

The Prognostic Value of Anti-PLA2R Antibodies Levels in Primary Membranous Nephropathy

International Journal of Molecular Sciences, 2023
Anti-PLA2R antibodies (Ab) are a diagnostic and prognostic biomarker in primary membranous nephropathy (PMN). We assessed the relationship between the levels of anti-PLA2R Ab at diagnosis and different variables related to disease activity and prognosis in a western population of PMN patients.
Boris Gilburd, Pazit Beckerman
exaly   +3 more sources

Anti-PLA2R antibody reduction as a predictor of treatment response in primary membranous nephropathy: a retrospective study. [PDF]

J Bras Nefrol
Abstract Introduction: Primary membranous nephropathy (PMN) is a leading cause of nephrotic syndrome in adults. Although proteinuria has been the conventional guiding parameter in disease monitoring, its limitations as a non-specific and delayed marker have led to the appeal of anti-phospholipase A2 receptor antibodies (PLA2R) as specific and ...
Bashir K, Asghar MR, Saleem N, Shahzil M, Riaz A, Hashmi MN, Sheraz A.   +6 more
europepmc   +4 more sources

The relationship of anti-phospholipase A2 receptor antibody and C5a complement with disease activity and short-term outcome in idiopathic membranous nephropathy

Journal of the Formosan Medical Association, 2019
Background: The binding of anti-phospholipase A2 receptor (anti-PLA2R) antibody to podocyte and complement activation is the mechanisms of idiopathic membranous nephropathy (IMN).
Jyun Ni Chi, Tai Shuan Lai, Ching Fang Wu, Tian Yi Fu, Yu Hsiang Chou, Yen Ling Chiu, Wei Chou Lin, Wen Chih Chiang, Yung Ming Chen, Ming Shiou Wu   +9 more
doaj   +2 more sources

Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody [PDF]

PeerJ, 2020
Background To discuss the clinicopathological features and prognosis of patients with idiopathic membranous nephropathy (IMN) who are serum-negative for the anti-PLA2R antibody.
Wenkai Guo, Yan Zhang, Caifeng Gao, Jing Huang, Jiatong Li, Rong Wang, Bing Chen   +6 more
doaj   +3 more sources

Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy

Kidney Research and Clinical Practice, 2018
Background: Phospholipase A2 receptor (PLA2R) has been identified as a major autoantigen in primary membranous nephropathy (MN). We evaluated the association between anti-PLA2R antibodies and clinical outcome in Korean patients with primary MN.
Eun Joo Song, Kye Hwa Jeong, Young Ae Yang, Jeong-Hoon Lim, Hee-Yeon Jung, Ji-Young Choi, Jang-Hee Cho, Chan-Duck Kim, Yong-Lim Kim, Sun-Hee Park   +9 more
doaj   +2 more sources